Low-dose radiotherapy in diffuse large B-cell lymphoma

2016 ◽  
Vol 35 (4) ◽  
pp. 472-479 ◽  
Author(s):  
Carlo Furlan ◽  
Vincenzo Canzonieri ◽  
Michele Spina ◽  
Mariagrazia Michieli ◽  
Anna Ermacora ◽  
...  
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Low Dose Radiotherapy ◽  
Large B Cell

Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib

2019 ◽  
Vol 98 (10) ◽  
pp. 2433-2436
Author(s):  
Annie Pang ◽  
Rex Au-Yeung ◽  
Rock Y.Y. Leung ◽  
Yok-Lam Kwong
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

2019 ◽  
Vol 37 ◽  
pp. 569-569
Author(s):  
N.L. Berinstein ◽  
I.A. Bence-Buckler ◽  
P. Laneuville ◽  
D. Stewart ◽  
L. Smyth ◽  
...  
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Phase 2 Study ◽  
Large B Cell

A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e14578-e14578 ◽  
Author(s):  
Neil Lorne Berinstein ◽  
Richard H. C. Van Der Jagt ◽  
Matthew C. Cheung ◽  
Rena Buckstein ◽  
Mohan Karkada ◽  
...  
Keyword(s):  
Clinical Trial ◽  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phase 2 ◽  
Large B Cell Lymphoma ◽  
Trial Testing ◽  
Phase 2 Clinical Trial ◽  
Large B Cell

Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma

2015 ◽  
Vol 56 (9) ◽  
pp. 2613-2618 ◽  
Author(s):  
Yingying Cui ◽  
Xin Li ◽  
Zhenchang Sun ◽  
Changsen Leng ◽  
Ken Young ◽  
...  
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Safety And Efficacy ◽  
Conventional Dose ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Conventional Dose Chemotherapy

Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma

2019 ◽  
Vol 98 (9) ◽  
pp. 2227-2230
Author(s):  
Thomas S. Y. Chan ◽  
Pek-Lan Khong ◽  
Rex Au-Yeung ◽  
Yok-Lam Kwong ◽  
Eric Tse
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
B Cell ◽  
Low Dose ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
Large B Cell Lymphoma ◽  
Durable Complete Response ◽  
Large B Cell
Sign in / Sign up

Export Citation Format

Share Document